Eli Lilly to purchase Endo Pharmaceuticals

[Anonymous]

The word is that our old buddy Dave Holvek, now CEO at Endo is setting Endo up for a Lilly buyout.

 

[Anonymous]

Endo Pharmaceuticals Holdings Inc., through its subsidiary, Endo Pharmaceuticals Inc., engages in the research, development, manufacture, marketing, and sale of branded and generic prescription pharmaceuticals in the United States. Its primary products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana and Opana ER, and Percocet for the relief of moderate to severe pain; Voltaren Gel for use in treating pain associated with osteoarthritis; Frova for the acute treatment of migraine headaches in adults; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas for the palliative treatment of advanced prostate cancer; Valstar, a sterile solution for intravesical instillation of valrubicin and BCG-refractory CIS of the bladder; Hydron Implant, a reservoir-based drug delivery system available for parenteral administration; Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; and Sanctura XR to treat OAB symptoms. The company also offers generic products, including Endocet and morphine sulfate. In addition, it provides various development stage products, which primarily comprise Aveed for the treatment of male hypogonadism; Fortesta for testosterone replacement therapy in male hypogonadism; Octreotide implant for the treatment of acromegaly; Urocidin for the treatment of non-muscle-invasive bladder cancer that is currently undergoing Phase III clinical testing; and Axomadol in Phase II development for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The company has a strategic alliance agreement with Penwest Pharmaceuticals Co.; and a collaboration agreement with Orion Corporation. Endo Pharmaceuticals Holdings was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania.

Source: Yahoo Finance.

 

[Anonymous]

The word is that our old buddy Dave Holvek, now CEO at Endo is setting Endo up for a Lilly buyout.

Great news for you, if you are holding Endo. Don't wait until Lilly declares 15% dividend, and the stock prices at $4.23.

 

[Anonymous]

Hmmmmm...Endo just bought AMS last week...

 

[Anonymous]

Hmmmmm...Endo just bought AMS last week...

Maybe in a few years, Endo will by LLY.